Literature DB >> 21644867

Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration?

Ken J Harvey, Richard O Day, William G Campbell, Wendy Lipworth.   

Abstract

The cost differential between these two drugs is no longer defensible.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21644867

Source DB:  PubMed          Journal:  Med J Aust        ISSN： 0025-729X            Impact factor:   7.738


  2 in total

1.  Comparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis.

Authors:  Xiao-Yu Zhang; Xiao-Fan Guo; Shao-Dan Zhang; Jing-Na He; Cao-Yu Sun; Yin Zou; Han-Si Bi; Yang Qu
Journal:  Int J Ophthalmol       Date:  2014-04-18       Impact factor: 1.779

2.  The challenge of costly drugs.

Authors:  Charles Denaro; Jennifer Martin
Journal:  Aust Prescr       Date:  2016-06-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.